ClinicalTrials.gg

Program

Ethinyl Estradiol

Also written as “Gestodene/EE Patch (BAY86-5016)”, “Ethinylestradiol/Gestodene (BAY86-5016)” and “Levonorgestrel/Ethinyl Estradiol”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Metrorrhagia · Premenstrual Syndrome · Hemorrhage · Hot Flashes, led by 5 companies.

Furthest: phase 4, since Dec 2, 200544 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson150 open or runningphase 4since Dec 2, 2005Oct 7, 2005none ahead
Bayer130 open or runningphase 4since Sep 12, 2005Sep 9, 2005none ahead
Teva Pharmaceutical Industries80 open or runningphase 3since Sep 12, 2005Sep 12, 2005none ahead
Pfizer70 open or runningphase 3since Aug 8, 2005Aug 8, 2005none ahead
agile-therapeutics10 open or runningphase 2since Nov 29, 2010Nov 29, 2010none ahead

Also a collaborator on its studies: novum, Eli Lilly and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since Aug 8, 2005.

  1. Sep 4, 2009Phase 3 study in HemorrhageBayer · NCT00984789 · 393 enrolled · Austria, Czech Republic, Netherlands
  2. Oct 15, 2009Phase 3 study in Pregnancy PreventionTeva Pharmaceutical Industries · NCT00996580 · 3,597 enrolled · United States
  3. Mar 8, 2010Phase 1 study in ContraceptionBayer · NCT01083264 · 43 enrolled · Germany
  4. Sep 16, 2010Phase 2 study in ContraceptionBayer · NCT01204190 · 173 enrolled · Germany, Netherlands
  5. Nov 29, 2010agile-therapeutics's first study: phase 2 study in Ovulation SuppressionNew to agile-therapeuticsagile-therapeutics · NCT01250210 · 123 enrolled · United States
  6. Feb 4, 2011Phase 1 study in Follicle DevelopmentTeva Pharmaceutical Industries · NCT01291004 · 206 enrolled · United States
  7. Apr 20, 20112 phase 1 studiesTeva Pharmaceutical Industries · NCT01340625, NCT01344369
  8. Jul 1, 2011Phase 2 study in ThrombosisTeva Pharmaceutical Industries · NCT01388491 · 293 enrolled · Germany, Israel, Italy and more
  9. Apr 29, 2014Phase 1 study in HealthyJohnson & Johnson · NCT02127593 · 101 enrolled · Netherlands
  10. Sep 2, 2015Phase 2 study in ContraceptionBayer · NCT02550977 · 91 enrolled · Russian Federation, Ukraine
  11. Apr 13, 2017Phase 1 study in HealthyJohnson & Johnson · NCT03126097 · 18 enrolled · United States
  12. Aug 11, 2017Phase 1 study in HealthyJohnson & Johnson · NCT03249402 · 24 enrolled · Belgium
  13. May 24, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03547024 · 14 enrolled · Belgium
  14. Sep 5, 2018Phase 1 study in Healthy FemalesPfizer · NCT03662516 · 17 enrolled · United States

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha agonist”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 44 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03662516Healthy Females · United States1CompletedPfizerJan 19, 201917
NCT03547024Healthy · Belgium1CompletedJohnson & JohnsonAug 30, 201814
NCT03249402Healthy · Belgium1CompletedJohnson & JohnsonNov 24, 201724
NCT03126097Healthy · United States1TerminatedJohnson & JohnsonMay 26, 201718
NCT02550977Contraception · Russian Federation, Ukraine2CompletedBayerJul 15, 201691
NCT02127593Healthy · Netherlands1CompletedJohnson & JohnsonSep 2014101
NCT01388491Thrombosis · Germany, Israel, Italy and more2CompletedTeva Pharmaceutical IndustriesSep 30, 2012293
NCT01344369Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200836
NCT01340625Bioequivalence · United States1CompletedTeva Pharmaceutical IndustriesJan 200736
NCT01291004Follicle Development · United States1CompletedTeva Pharmaceutical IndustriesMar 31, 2012206
NCT01250210Ovulation Suppression · United States2Completedagile-therapeuticsFeb 2008123
NCT01204190Contraception · Germany, Netherlands2CompletedBayerJul 2011173
NCT01083264Contraception · Germany1CompletedBayerMay 201043
NCT00996580Pregnancy Prevention · United States3CompletedTeva Pharmaceutical IndustriesSep 20113,597
NCT00984789Hemorrhage · Austria, Czech Republic, Netherlands3CompletedBayerSep 2010393
NCT00933179Contraception · Germany2CompletedBayerSep 201030
NCT00924560Bone Mineral Density · United States2CompletedTeva Pharmaceutical IndustriesAug 20121,361
NCT00910637Contraception · United States3CompletedBayerDec 13, 20101,502
NCT00915915Contraception · Germany2CompletedBayerApr 2010108
NCT00914693Contraception · Argentina, Australia, Chile and more3CompletedBayerSep 20111,694
NCT00873483Contraception · United States2CompletedBayerMar 3, 2010173
NCT00745901Hemorrhage4CompletedJohnson & JohnsonOct 2008355
NCT00729404Contraception · Germany2TerminatedBayerFeb 200917
NCT00709982Drug Interactions1CompletedJohnson & Johnson47
NCT00709332Drug Interactions1CompletedJohnson & Johnson47
NCT00653016Female Contraception4CompletedJohnson & Johnson405
NCT00447863Contraception1WithdrawnPfizer0
NCT00394771Metrorrhagia · United States2CompletedTeva Pharmaceutical IndustriesMar 2008567
NCT00344383Metrorrhagia2CompletedJohnson & Johnson61
NCT00320580Metrorrhagia2CompletedJohnson & Johnson239
NCT00320567Osteoporosis2CompletedJohnson & Johnson123
NCT00319163Healthy · United States1CompletedPfizerNov 200626
NCT00310531Bone Diseases, Metabolic3CompletedBayer500
NCT00307632Contraception · Brazil, Mexico4CompletedJohnson & JohnsonDec 2004580
NCT00261482Contraception4CompletedJohnson & Johnson778
NCT00254189Ovulation2CompletedPfizer60
NCT00236782Contraception3CompletedJohnson & Johnson1,517
NCT00236769Contraception3CompletedJohnson & Johnson1,751
NCT00195559Premenstrual Syndrome · Argentina, Brazil, Chile and more3CompletedPfizer526
NCT00206622Hot Flashes · United States4CompletedBayer425
NCT00196326Contraception · United States3CompletedTeva Pharmaceutical IndustriesJun 20072,235
NCT00185237Hot Flashes3CompletedBayerNov 2006165
NCT00161681Premenstrual Syndrome · United States3CompletedPfizerAug 2006200
NCT00128934Menstruation Disturbances · United States, Canada3CompletedPfizer744

How it is read

Names in the registry

  • “Gestodene/EE Patch (BAY86-5016)”, 9 entries
  • “Ethinylestradiol/Gestodene (BAY86-5016)”, 6 entries
  • “Levonorgestrel/Ethinyl Estradiol”, 5 entries
  • “Ethinylestradiol”, 4 entries
  • “ethinyl estradiol and levonorgestrel; exenatide”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.